2,2-Dimethyl-3-oxo-1-butyl trifluoroacetate | 24706-87-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2-Dimethyl-3-oxo-1-butyl trifluoroacetate
• 英文别名: 2,2-dimethyl-3-oxobutyl 2,2,2-trifluoroacetate；3,3-dimethyl-4-trifluoroacetoxy-butan-2-one；2,2-dimethyl-3-oxobutyl trifluoroacetate；3,3-dimethyl-4-hydroxy butanone trifluoroacetate ester；3,3-dimethyl-4-hydroxybutan-2-one trifluoroacetate ester；(2,2-dimethyl-3-oxobutyl) 2,2,2-trifluoroacetate
• CAS: 24706-87-4
• 化学式: C₈H₁₁F₃O₃
• 分子量: 212.169
• InChiKey: VWCFYYANRJWCFW-UHFFFAOYSA-N

物化性质

• 沸点：
  53-55 °C(Press: 2 Torr)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,2-Dimethyl-3-oxo-1-butyl trifluoroacetate 在 吡啶 、 溴 、 碳酸氢钠 、 lithium chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 64.0h， 生成 1,1-dimethyl-2-chloroethyl bromomethyl ketone
  参考文献：
  名称：

  Synthesis of 1-Amino-2,2-dialkylcyclopropanecarboxylic Acids via Base-Induced Cyclization of .gamma.-Chloro-.alpha.-imino Esters

  摘要：

  beta-Chloro ketones were oxidatively transformed into alpha-keto carboxylic esters and condensed with primary amines in the presence of titanium(IV) chloride. Base-induced cyclization of the resulting gamma-chloro-alpha-imino esters, incorporating suitable N-substituents, led directly to 1-amino-2,2-dialkyl- cyclopropanecarboxylic ester derivatives via a 1,5-dehydrochlorination process. Syntheses of different N- and/or carboxyl-protected geminally (gem) dialkylated cyclopropane amino acids were developed, while access to the free alpha-amino acids is also given. The methodology used was further extended by reduction of the gamma-chloro-alpha-imino esters to functionalized gamma-chloro-alpha-amino esters,prior to ring closure, affording N-alkyl-gem-dialkyl-1-aminocyclopropanecarboxylic acid derivatives.

  DOI：

  10.1021/jo00102a022
• 作为产物：
  描述：

  2,2-dimethyl-1-tosyloxy-butan-3-one 、 三氟乙酸 在 sodium 2,2,2-trifluoroacetate 作用下， 生成 2,2-Dimethyl-3-oxo-1-butyl trifluoroacetate
  参考文献：
  名称：

  1,4-羰基参与烷基甲苯-对磺酸盐的溶剂分解

  摘要：

  2，2-二甲基-3-氧代-3-苯基丙基甲苯对磺酸酯（甲苯磺酸酯）和一些相关的3-氧代烷基甲苯磺酸酯通过1，4-羰基参与溶剂化在缓冲的羧酸溶剂中，得到未重排的羧酸酯。该反应太快而不能直接取代，并且在缺少羰基的类似化合物中不会发生。同一系列的仲烷基甲苯磺酸盐也通过1,4-羰基参与反应，但发生中间阳离子片段，并与溶剂反应生成未重排的产物。

  DOI：

  10.1039/p29750000372

文献信息

• [EN] N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES DE PIPERIDINYL-IMIDAZOPYRIDINE N-SUBSTITUES UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2004026868A1

  公开（公告）日：2004-04-01

  This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α are selected from the group consisting of aryl groups, hydroxy groups, oxo groups, etc.; said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, etc.; or a pharmaceutically acceptable amide of such compound, or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中R1代表氢原子或卤原子；R2代表氢原子，等等；R3代表具有1至10个碳原子的烷基基团；R3中的烷基基团被来自α取代基组的至少一个取代基所取代；所述α取代基选自芳基、羟基、酮基等组成的组；所述芳基含有6至10个碳原子；所述芳基未取代或被具有1至6个碳原子的至少一个烷基基团所取代；所述杂环基团和杂环基团中的杂环基在杂环羰基中是含有1至4个来自氮原子等组成的杂原子的5至10元环基团；或者是该化合物的药学上可接受的酰胺，或者是该化合物的药学上可接受的酯，以及其药学上可接受的盐。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。
• BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES
  申请人：WENDER PAUL A.

  公开号：US20090270492A1

  公开（公告）日：2009-10-29

  Biologically active compounds related to the bryostatin family of compounds, including methods of utilizing the same.

  与拟静脉注射家族相关的生物活性化合物，包括利用这些化合物的方法。
• 2,2-Disubstituted 4-Acylthio-3-oxobutyl Groups as Esterase- and Thermolabile Protecting Groups of Phosphodiesters
  作者：Emilia Kiuru、Zafar Ahmed、Harri Lönnberg、Leonid Beigelman、Mikko Ora

  DOI：10.1021/jo302421u

  日期：2013.2.1

  2-substituents and the size of the acylthio group. The acyl group evidently migrates from the sulfur atom to C3-gem-diol obtained by hydration of the keto group and the exposed mercapto group attacks on C1 resulting in departure of the protecting group as 4,4-disubstituted 3-acyloxy-4,5-dihydrothiophene with concomitant release of the desired phosphodiester.

  已经引入了五个不同的2，2-二取代的4-酰基硫基-3-氧代丁基作为酯酶不稳定的磷酸二酯保护基，它们另外是热不稳定的。的磷酸三酯1 - 3通过HPLC-ESI-MS制备，以确定在37酶和非酶去除这些基团的速率℃和pH 7.5。另外，1 H NMR光谱监测用于中间体和产物的结构表征。当用猪肝酯酶处理时，这些基团通过酶促脱酰基作用，然后快速化学环化成4,4-二取代的二氢噻吩-3（2 H）-一。可以通过4-酰硫基取代基的性质来调节酶促脱保护的速率，苯甲酰基和乙酰基的去除速度是新戊酰基的50和5倍。酶促脱保护后未观察到谷胱甘肽的烷基化。根据2-取代基的电负性和酰硫基的大小，非酶促脱保护的半衰期为0.57至35小时。酰基显然来自硫原子C3-迁移宝石由酮基的水合和产生保护基团的离去C1上的暴露的巯基的攻击得到二醇如4,4-二取代-3-酰氧基-4,5- -二氢噻吩并伴随释放所需的磷酸二酯。
• [EN] BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES<br/>[FR] ANALOGUES DE LA BRYOSTATINE, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2009052507A1

  公开（公告）日：2009-04-23

  Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.

  与拟静脉注射药物bryostatin家族相关的生物活性化合物，具有简化的间隔区域和/或改进的识别区域，包括其制备和利用方法。
• N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
  申请人：Pfizer Inc

  公开号：US20040127514A1

  公开（公告）日：2004-07-01

  This invention provides a compound of the formula (I): 1 or a pharmaceutically acceptable salt, amide or ester thereof, wherein R 1 represents a hydrogen atom or a halogen atom; R 2 represents a hydrogen atom, etc.; R 3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of R 3 is substituted by at least one substituent selected from the group consisting of substituents &agr;; said substituents &agr; is aryl, hydroxy, oxo, etc.; said aryl having 6 to 10 carbon atoms; said aryl is unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents &agr;, are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了化合物(I)的化合物：1或其药学上可接受的盐，酰胺或酯，其中R1代表氢原子或卤素原子; R2代表氢原子等; R3代表具有1到10个碳原子的烷基基团; R3的烷基基团被选自取代基&agr;的至少一种取代; 该取代基&agr;是芳基，羟基，氧代或其他; 该芳基具有6到10个碳原子; 该芳基未取代或被至少一个具有1到6个碳原子的烷基基团取代; 该杂环和该杂环羰基的杂环基团，取代基&agr;均为5至10个成员的环状基团，包含1至4个选自氮原子，氧原子和硫原子的杂原子。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征或类似疾病的治疗有用。本发明还提供了包含上述化合物的制药组合物。